External Radiation Dose to Owners of Canines Treated with (117mSn) Radiosynoviorthesis for Osteoarthritis

A novel device in the veterinary market uses a colloid containing radioactive 117mSn to treat osteoarthritis in the synovial joints of canines. The technique of injecting a radioisotope to restore synovia is referred to as radiosynoviorthesis. The outpatient canine procedure uses a maximum administr...

Full description

Saved in:
Bibliographic Details
Published inHealth physics (1958)
Main Authors Smith, Chad A, Krimins, Rebecca A
Format Journal Article
LanguageEnglish
Published United States 01.08.2022
Online AccessGet more information

Cover

Loading…
More Information
Summary:A novel device in the veterinary market uses a colloid containing radioactive 117mSn to treat osteoarthritis in the synovial joints of canines. The technique of injecting a radioisotope to restore synovia is referred to as radiosynoviorthesis. The outpatient canine procedure uses a maximum administration of 222 MBq of 117mSn injected into one or more joints. Due to the 13.91 d half-life and 158.6 keV gamma output of 117mSn, abiding by the annual public dose limit of 1 mSv is of primary regulatory concern. The therapy protocol starts with a pre-screening questionnaire to establish owner and animal behavior patterns. The questionnaire is used to determine the duration of written time and distance limitations post therapy. In this study, external radiation doses to owners were measured by providing optically stimulated luminescent dosimeters (OSLD) for up to 30 d post-treatment of the pet. Twelve owners were measured over various time frames at two licensed locations independent of each other. In one location, the average (OSLD) measured 0.029 mSv over a 14-d wear period. In the second location, the average (OSLD) measured 0.057 mSv over a 30-d wear period; both values were well below the recommended annual public dose. The overall average extrapolated external radiation dose was estimated at 0.092 mSv, while the maximum dose estimate was 0.25 mSv. The (OSLD) results and extrapolated owner doses provide reasonable assurance that the public dose limits will be met.
ISSN:1538-5159
DOI:10.1097/HP.0000000000001579